Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Cut to $51.00 by Analysts at Raymond James

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective cut by Raymond James from $52.00 to $51.00 in a report issued on Tuesday, PriceTargets.com reports. They currently have a strong-buy rating on the stock.

Other analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Mirum Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, August 10th. SVB Leerink decreased their target price on shares of Mirum Pharmaceuticals from $33.00 to $32.00 and set an outperform rating on the stock in a research note on Monday. Finally, HC Wainwright reissued a buy rating on shares of Mirum Pharmaceuticals in a research note on Friday, August 6th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of Buy and a consensus price target of $37.20.

Shares of Mirum Pharmaceuticals stock opened at $17.82 on Tuesday. The firm’s 50 day moving average is $15.63 and its 200 day moving average is $17.23. The firm has a market capitalization of $543.80 million, a PE ratio of -3.29 and a beta of 2.30. Mirum Pharmaceuticals has a 1 year low of $13.85 and a 1 year high of $26.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Thursday, August 5th. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($1.04). As a group, equities research analysts predict that Mirum Pharmaceuticals will post -5.22 EPS for the current year.

In other news, major shareholder James E. Flynn sold 49,239 shares of the company’s stock in a transaction dated Tuesday, July 6th. The shares were sold at an average price of $16.20, for a total transaction of $797,671.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder James E. Flynn sold 10,599 shares of the company’s stock in a transaction dated Friday, July 2nd. The shares were sold at an average price of $17.01, for a total transaction of $180,288.99. The disclosure for this sale can be found here. In the last three months, insiders sold 159,163 shares of company stock worth $2,548,289. 62.50% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new position in shares of Mirum Pharmaceuticals during the second quarter valued at about $44,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Mirum Pharmaceuticals during the second quarter valued at about $52,000. Point72 Asset Management L.P. acquired a new position in shares of Mirum Pharmaceuticals during the first quarter valued at about $99,000. California State Teachers Retirement System raised its holdings in shares of Mirum Pharmaceuticals by 9.9% in the 1st quarter. California State Teachers Retirement System now owns 8,696 shares of the company’s stock worth $172,000 after acquiring an additional 780 shares during the last quarter. Finally, Pinnacle Advisory Group Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the 1st quarter worth about $198,000. Hedge funds and other institutional investors own 76.74% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O’Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Featured Story: Cost of Capital

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.